Subscribe To
OMER / Omeros: On Death's Door
OMER News
By Reuters
October 16, 2023
Omeros to terminate kidney disease trial as therapy fails late-stage study
Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of more_horizontal
By Seeking Alpha
July 21, 2023
Omeros Corporation - Still Looking Too Risky For A Buy Rating
Omeros Corporation's share price has seen significant run-ups in recent months despite disappointing first quarter results in 2023 and the company's l more_horizontal
By Business Wire
June 21, 2023
Omeros Announces Webcast Details for Annual Meeting of Shareholders
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareh more_horizontal
By The Motley Fool
June 12, 2023
Why Shares of Omeros Dropped on Monday
The company's lead therapy, Narsoplimab, has not yet been approved. As of the first quarter, Omeros had $371.4 million in cash. more_horizontal
By Seeking Alpha
May 9, 2023
Omeros Corporation (OMER) Q1 2023 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations G more_horizontal
By Seeking Alpha
March 13, 2023
Omeros Corporation (OMER) Q4 2022 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relatio more_horizontal
By The Motley Fool
February 9, 2023
Why Omeros Stock Bolted Higher This Week
A $200 million milestone payment sparked a rally in the biopharma's shares this week. more_horizontal
By Seeking Alpha
February 8, 2023
Omeros: $200M Added To The Company's Balance Sheet, Upgrading To Strong Buy
Omeros Corporation's stock has rallied 66% on Feb 6th based on the milestone payment of $200M, which eliminated the potential cash runway overhang som more_horizontal